Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF)

What Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) does

Medexus Pharmaceuticals, Inc. (TSX: MDP, OTCQX: MEDXF) is a publicly traded Canadian specialty pharmaceutical company headquartered in Toronto that develops and commercializes treatments for orphan diseases and rare conditions across North America. The company's portfolio is organized into two regional franchises, a Canadian Product Portfolio and a US Product Portfolio, spanning five therapeutic areas: allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Core assets include GRAFAPEX (treosulfan) for Injection, a hematology/oncology product reported as showing strong product-level performance in Fiscal Year 2026, and UM171 Cell Therapy, a cell therapy asset recently licensed for the Canadian market through a June 2026 license and supply deal.

Medexus operates a fully integrated North American commercial infrastructure that spans commercial operations, supply chain, regulatory, medical affairs, and a direct salesforce covering both the United States and Canada. The company's go-to-market is an enterprise field sales model targeting healthcare professionals and patients who need access to specialty treatments for rare and orphan conditions. Products are priced and reimbursed through standard healthcare provider and payer channels; specific pricing is not publicly disclosed.

The company generates revenue through one-time license and product sales of its specialty pharmaceutical portfolio, with product-level exclusivity in rare disease indications acting as the primary value driver. Customer segments are horizontal, comprising individual patients and a broad base of prescribing physicians and specialists across allergy, hematology, oncology, rheumatology, and dermatology. There is no disclosed AI/ML capability, no named anchor customers, and no disclosed headcount, and recent corporate activity in 2026 has centered on portfolio expansion through licensing deals and the commercial ramp of GRAFAPEX rather than on restructuring or capital raises.

Name

Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF)

Legal name

Medexus Pharmaceuticals, Inc.

Website

https://medexuspharma.com

Company type

Public

Operating status

Operating

Headcount range

101–250 employees

Short description

Medexus Pharmaceuticals is a publicly traded Canadian specialty pharma company (TSX: MDP, OTCQX: MEDXF) that develops and commercializes orphan and rare disease treatments across allergy, dermatology, hematology, oncology, and rheumatology in North America via an integrated direct salesforce.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Specialty pharmaceuticals
• Orphan drug treatments
• Rare disease therapeutics
• Hematology oncology drugs
• Rheumatology allergy products

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Specialty Pharmaceutical Product Sales: Medexus generates revenue through the sale of specialty pharmaceutical products focused on orphan drugs and rare disease treatments. The company has a portfolio of products addressing allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology conditions distributed through their integrated North American commercial infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Medexus Pharmaceuticals develops and commercializes specialty and rare disease pharmaceutical products across five therapeutic areas: allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. The company markets prescription drugs such as GRAFAPEX (treosulfan) for Injection and distributes a licensed cell therapy (UM171) in Canada, using a fully integrated North American infrastructure that spans commercial operations, supply chain, regulatory, medical affairs, and salesforce.

Product overview

Medexus Pharmaceuticals is a specialty pharmaceutical company with a diversified product portfolio of specialty and rare disease products organized into two regional portfolios (Canadian and US). The company focuses on five therapeutic areas: allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Key products include GRAFAPEX (treosulfan) for Injection, a hematology/oncology treatment, and the licensed UM171 Cell Therapy. The company operates with fully integrated infrastructure including commercial operations, supply chain, regulatory, medical affairs, and salesforce capabilities across North America.

Differentiator

Problem solved

Functional benefit

Products and services

• GRAFAPEX (treosulfan) for Injection A specialty pharmaceutical product indicated for injection use in hematology/oncology, specifically for rare disease treatment. Distributed by Medexus as part of its US product portfolio.
• UM171 Cell Therapy A cell therapy product licensed for the Canadian market under a license and supply deal announced in June 2026. Represents an expansion into advanced hematology treatments for rare diseases.
• Canadian Product Portfolio A portfolio of specialty pharmaceutical products distributed in Canada covering allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology therapeutic areas.
• US Product Portfolio A portfolio of specialty pharmaceutical products distributed in the United States covering allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology therapeutic areas.

Quantifiable outcome

• Strong product-level performance of GRAFAPEX (treosulfan) for Injection demonstrated in Fiscal Year 2026 results

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• UM171 Cell Therapy LicensorcoreOEM/ Whitelabel/ Licensing Partner · 9 June 2026Medexus announced a license and supply deal for UM171 Cell Therapy in Canada. This partnership expands the company's rare disease and orphan drug portfolio by bringing cell therapy treatments to the Canadian market. The deal was announced in June 2026 and represents a strategic expansion into cell therapy treatments.

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Emerging players

• Assertio Holdings: Specialty pharmaceutical company commercializing differentiated treatments in neurology, inflammation, and pain. Comparable to Medexus as a smaller U.S. specialty pharma focused on branded specialty therapeutics with a similar GTM approach.
• Tris Pharma: Specialty pharmaceutical company focused on ADHD, pain, and other specialty therapeutic areas. Comparable as a smaller specialty pharma peer with an integrated development and commercialization model focused on differentiated formulations.

Broad incumbents

• Endo International: Specialty pharmaceutical company with branded specialty therapeutics across multiple therapeutic areas. Comparable through its branded specialty portfolio focus, though materially larger in scale than Medexus.
• Bausch Health Companies: Large specialty pharmaceutical company with a diversified portfolio including specialty brands and rare disease franchises. Broader incumbent with overlapping specialty therapeutic categories but wider product breadth than Medexus.

Direct peers

• HLS Therapeutics: Canadian-listed specialty pharmaceutical company commercializing products across specialty therapeutic areas in North America. Directly comparable to Medexus as a similar-sized Canadian specialty pharma with a focused product portfolio and similar GTM approach.
• Knight Therapeutics: Canadian specialty pharmaceutical company that acquires, in-licenses, and commercializes specialty pharmaceutical products primarily in Canada and select international markets. Directly comparable to Medexus's strategy of building a North American specialty portfolio through in-licensing.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with significant rare disease, immunology, and specialty brands exposure. Comparable to Medexus as a specialty pharma peer focused on underserved patient populations with branded specialty therapeutics.
• Theratechnologies: Canadian specialty biopharmaceutical company focused on oncology and HIV therapies. Comparable to Medexus through its Canadian listing, North American commercialization model, and focus on specialty therapeutics in oncology.
• Amneal Pharmaceuticals: Specialty and generics pharmaceutical company with a growing specialty therapeutics franchise including injectables. Comparable to Medexus through its specialty injectable portfolio and U.S. commercial focus on underserved therapeutic categories.
• Jazz Pharmaceuticals: Specialty pharmaceutical company with a major hematology/oncology and rare disease franchise. Comparable to Medexus through its focus on high-value specialty therapeutics, orphan drug commercialization, and integrated North American commercial infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/MedexusInc
• LinkedInlinkedin.com/company/medexuspharma

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF)